MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, n patients with refractory HR+/HER2- metastatic breast cancer

1. Dickler, M.N.
2. Tolaney, S.M.
3. Rugo, H.S.
4. Cortes, J.
5. Dieras, V.
6. Patt, D.
7. Wildiers, H.
8. Hudis, C.A.
9. O'Shaughnessy, J.
10. Zamora, E.
11. Yardley, D.A.
12. Frenzel, M.
13. Koustenis, A.
14. Baselga, J.